Author

Michał Mikula

h-index 7 View on Semantic Scholar

We have 3 of 20 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cardiovascular biomarker phenotype associated with immune checkpoint inhibitor therapy in patients with non-small cell lung cancer: an exploratory blood transcriptome study

Background Immune checkpoint inhibitors (ICIs) have transformed the management of advanced non-small cell lung cancer (NSCLC), but their use is associated with potentially serious immune-related cardiotoxicity, often reflected by elevations in N-terminal pro-B-type natriuretic peptide (NT-proBNP). Identifying patients...

Joanna Ziemska-Legięcka, N. Żeber-Lubecka, Magdalena Borucka et al. · Frontiers in Immunology · 0 citations

Open access Aug 2026

Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML

Findings identify CDK8 as a transcriptional node of LSC-associated programs and provide a mechanistic rationale for combined CDK8-BET inhibition in molecularly defined AML subsets, which will require validation in functional LSC assays and primary specimens.

M. Statkiewicz, I. Rumieńczyk, U. Pakulska et al. · Cells · 0 citations

Review Open access Aug 2026

Cancer Without a Map: Navigating Cancer of Unknown Primary Through Molecular Profiling.

Evidence indicates that molecularly guided therapy, particularly when integrated with clinicopathological data, can improve survival and expand treatment options beyond empirical chemotherapy.

K. Tałasiewicz, Michał Mikula, Aleksandra Kapała · Critical reviews in oncology... · 0 citations